课题基金 / 基金详情

ACTG 277--DAPSONE VERSUS ATOVAQUONE FOR PCP PROPHYLAXIS IN HIV INFECTED PATIENTS

ACTG 277--DAPSONE VERSUS ATOVAQUONE FOR PCP PROPHYLAXIS IN HIV INFECTED PATIENTS
ACTG 277——氨苯砜与阿托伐醌用于 HIV 感染患者预防 PCP 的比较
批准号：
6276937
负责人：
Fred T Valentine
金额：
$2.03万
依托单位：
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
项目状态：
已结题
起止时间：
1997-12-01 至 1998-11-30
来源：
https://reporter.nih.gov/project-details/6276937
关键词：
HIV infections Pneumocystis carinii Pneumocystis pneumonia antiprotozoal agents atovaquone chemoprevention clinical research clinical trials dapsone human subject human therapy evaluation opportunistic infections

项目摘要

项目成果

Fred T Valentine的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This is a multicenter, randomized, comparative study of two prophylactic regimens (daily dapsone and daily atovaquone) in HIV-infected patients with either a history of PCP or a CD4+ cell count of < 200/mm3 or < 15% of the total lymphocyte count, who are intolerant of trimethoprim and/or sulfonamides. The two regimens will be compared as to toxicity; incidence of the combined endpoint of PCP, extrapulmonary pneumocystosis, and death; incidence of toxoplasmosis; and mortality rates.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Center for AIDS Research
Administrative
Immunopathogenesis of acute and early HIV infection
CD4 RESPONSES TO ANTIRETROVIRAL THERAPY (ART) ALONE OR ART WITH VACCINATION
海外基金